NCT02072720

Angiogenic Factor Expression During Fractionated Irradiation

Pilot Study to Determine the Effect of Fractionated Radiotherapy on Expression of Pro-angiogenic Factors in Oesophagus Carcinoma

• Status: Unknown
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 40 (estimated)
• Sponsor: Amsterdam UMC, location VUmc · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The main question of this study is if and when VEGF (vascular endothelial growth factor) expression in the tumor is upregulated during chemoradiation and if bevacizumab inhibits subsequent vessel growth in the tumor. * Therefore the first aim of this study is to identify the time point of induction of VEGF in the tumor tissue of esophagus carcinoma during chemoradiation (after 1,2,3 or 4 weeks of chemoradiation). * If we identify increased expression of VEGF at a certain time point, our second aim is to determine if we can inhibit the subsequent tumor vessel growth by administration of bevacizumab.

Conditions

• Primary Esophageal Carcinoma

Interventions

Type	Name	Description
DRUG	Bevacizumab	patients will receive bevacizumab (3mg/kg/wk) starting from the identified induction time point of VEGF expression

Timeline

• Start date: 2014-02-01
• Primary completion: 2021-03-01
• Completion: 2021-05-01
• First posted: 2014-02-26
• Last updated: 2019-10-02

Locations

3 sites across 1 country: Netherlands